Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 4/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 4/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24933247 | 0.88 | PTGES (0.39) | HSD17B1HSD17B2DGAT1PTGES | |
| SCHEMBL24933248 | 0.85 | HSD17B1 (0.35) | HSD17B1HSD17B2DGAT1 | |
| SCHEMBL24933838 | 0.84 | IRAK4 (0.38) | HSD17B1HSD17B2PTGES | |
| SCHEMBL24933664 | 0.81 | HSD17B1 (0.35) | HSD17B1HSD17B2DGAT1PTGES | |
| SCHEMBL30240698 | 0.81 | HSD17B1 (0.33) | HSD17B1HSD17B2 | |
| SCHEMBL24933407 | 0.80 | HSD17B1 (0.33) | HSD17B1HSD17B2DGAT1 | |
| SCHEMBL24932990 | 0.79 | HSD17B1 (0.36) | HSD17B1HSD17B2DGAT1 | |
| SCHEMBL24933256 | 0.78 | PDK2 (0.43) | HSD17B1HSD17B2 | |
| SCHEMBL24933219 | 0.76 | KCNH2 (0.47) | — | |
| SCHEMBL30240742 | 0.76 | KCNH2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | claimed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | claimed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | claimed |
| EP-4373809-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | Novartis AG (CH) | 2024-05-29 | — | — | EP | disclosed |
| CN-117980292-A | Substituted pyridone compounds for the treatment of orthomyxoviral infections | 诺华股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |
| WO-2023002443-A1 | SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS | NOVARTIS AG (CH) | 2023-01-26 | — | — | WO | disclosed |